Genenta Science (NASDAQ:GNTA) Releases Earnings Results, Beats Expectations By $0.28 EPS

Genenta Science (NASDAQ:GNTA) released its quarterly earnings data on Tuesday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.28, FiscalAI reports.

Genenta Science Trading Up 3.8%

Shares of Genenta Science stock opened at $0.70 on Thursday. Genenta Science has a 52 week low of $0.59 and a 52 week high of $10.00. The firm’s 50 day moving average is $0.91 and its two-hundred day moving average is $1.80.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Ghisallo Capital Management LLC acquired a new stake in Genenta Science during the 4th quarter worth $482,000. Weiss Asset Management LP acquired a new position in Genenta Science in the fourth quarter valued at $480,000. Norges Bank purchased a new position in shares of Genenta Science during the fourth quarter worth about $337,000. Alyeska Investment Group L.P. acquired a new stake in shares of Genenta Science during the fourth quarter worth about $328,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of Genenta Science during the fourth quarter worth about $26,000. 15.13% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.